PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-10.89%
Negative revenue growth while MCHP stands at 4.93%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-14.65%
Negative gross profit growth while MCHP is at 5.82%. Joel Greenblatt would examine cost competitiveness or demand decline.
-17.85%
Negative EBIT growth while MCHP is at 6.77%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-18.75%
Negative operating income growth while MCHP is at 6.70%. Joel Greenblatt would press for urgent turnaround measures.
-14.51%
Negative net income growth while MCHP stands at 24.12%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-13.94%
Negative EPS growth while MCHP is at 23.44%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-13.77%
Negative diluted EPS growth while MCHP is at 24.19%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.77%
Share reduction while MCHP is at 0.13%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.76%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
7.68%
Dividend growth at 75-90% of MCHP's 9.26%. Bill Ackman would press for a stronger return if the balance sheet allows.
-26.17%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-45.60%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
92.58%
10Y revenue/share CAGR under 50% of MCHP's 277.21%. Michael Burry would suspect a lasting competitive disadvantage.
35.39%
5Y revenue/share CAGR at 50-75% of MCHP's 63.79%. Martin Whitman would worry about a lagging mid-term growth trajectory.
43.56%
3Y revenue/share CAGR above 1.5x MCHP's 18.41%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
131.20%
10Y OCF/share CAGR under 50% of MCHP's 405.86%. Michael Burry would worry about a persistent underperformance in cash creation.
15.09%
Below 50% of MCHP's 85.83%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
19.89%
3Y OCF/share CAGR under 50% of MCHP's 58.26%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
812.98%
Net income/share CAGR above 1.5x MCHP's 276.45% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
520.08%
5Y net income/share CAGR above 1.5x MCHP's 156.41%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
88.83%
3Y net income/share CAGR 75-90% of MCHP's 114.02%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
63.37%
10Y equity/share CAGR at 50-75% of MCHP's 105.27%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
53.31%
5Y equity/share CAGR 1.25-1.5x MCHP's 44.48%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
68.54%
Positive short-term equity growth while MCHP is negative. John Neff sees a strong advantage in near-term net worth buildup.
487.06%
10Y dividend/share CAGR above 1.5x MCHP's 45.11%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
99.82%
5Y dividend/share CAGR above 1.5x MCHP's 36.68%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
37.51%
3Y dividend/share CAGR similar to MCHP's 38.82%. Walter Schloss finds parallel short-term dividend strategies for both companies.
-7.11%
Firm’s AR is declining while MCHP shows 15.32%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
14.68%
Inventory growth well above MCHP's 11.22%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
4.41%
Asset growth above 1.5x MCHP's 0.95%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
1.26%
75-90% of MCHP's 1.45%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
14.39%
We have some new debt while MCHP reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
0.70%
R&D dropping or stable vs. MCHP's 5.58%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-0.46%
We cut SG&A while MCHP invests at 5.46%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.